Data as of Mar 07
| -0.61 / -2.41%|
Arrowhead Research Corp. is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. It focuses on the preclinical and clinical development of therapeutics, in treating cancer and obesity, as well as healing wounded or diseased tissue. The company owns and operates two major subsidiaries: Calando Pharmaceuticals and Ablaris Therapeutics. Its main products include CALAA-01, an oncology drug and Adipotide, an anti-obesity peptide, which targets and kills the blood vessels that feed white adipose tissue. The company also delivers platforms, such as Dynamic Polyconjugate, Liposomal Nanoparticle, and RONDEL, which support preclinical and clinical candidates. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
|Christopher R. Anzalone||President, Chief Executive Officer & Director|
|Bruce D. Given||Chief Operating Officer|
|Kenneth Allen Myszkowski||Chief Financial Officer|
|David Lewis||Chief Scientific Officer|
|Jane Davidson||Secretary & Vice President-Administration|